KITLG and neoplasm: A recent proteomic analysis of plasma samples found lower levels of SCF in women that later developed BrC than in those that remained healthy, supporting SCF as a circulating biomarker, and indirectly suggesting an enhanced tumor controlling mechanism of SCF-activated MCs [55].